ImCheck Therapeutics News and Activities

ImCheck Therapeutics is owned by Ipsen.

Ipsen is one of the...

• CAC All-Trade;
• SBF 120;
• Stoxx 600;
• TOB Iconic 10,000.

Ipsen is a company listed under the stock ticker IPN (FR).

Ipsen has a direct presence in 4 countries.

Ipsen has 4 subsidiaries including ImCheck Therapeutics, Ipsen Iberica and Ipsen North America.

They are in:

• Pharmaceuticals80%
• Biotechnology20%

Acquisition, funding and merger involving Ipsen.

• Ipsen has announced the acquisition of ImCheck Therapeutics  (posted on October 23 2025).

View the org chart displaying its 12 main executives

Most searched biographies at ImCheck Therapeutics

• Pierre d'Epenoux, Chief Executive Officer and Director
• Sophie Agaugue, Vice President, Preclinical Research
• Maelle Miqueu, Data Science Manager

Popular executive movements at Ipsen

• Karen Witts, Independent Director, has left the company  (posted on May 14 2026).
• Emy Rossi has joined the company as Head of Talent Management and Operations  (posted on April 23 2026).
• Michelle Werner will join the company as Executive Vice President, President of North America on Mar. 23, 2026  (posted on March 13 2026).

Click here to view some more movements at Ipsen

Create your alert
to follow the executive moves at ImCheck Therapeutics.

Ipsen has 2,413 competitors including Lonza (Switzerland), Eurofins (Luxembourg) and Vertex Pharmaceuticals (United States (USA)).

Popular M&A news in Biotechnology

• Ollin Biosciences has just announced a $330 Million fundraising (posted on June 24 2026).
• RQ Biotechnology has just announced a $86 Million fundraising (posted on June 24 2026).
• Boundless Bio has filed its IPO. Its stock ticker will be AATD. (posted on June 23 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Carl Gordon - Director at Odyssey Therapeutics
• Jan Van de Winkel - President and Chief Executive Officer at Genmab

Learn more about the Biotechnology industry

Press releases by ImCheck Therapeutics

• ImCheck to Present Encouraging Interim Results in AML Patients from the EVICTION Trial at the 66th American Society of Hematology Meeting Annual Meeting
• ImCheck to Present Updated Data from the EVICTION Trial at the 39th Annual Meeting of the Society for Immunotherapy of Cancer
• ImCheck Receives FDA Fast Track Designation for ICT01 in Combination with Azacitidine and Venetoclax in First-Line Acute Myeloid Leukemia for Patients Unfit for Induction Chemotherapy Treatment
• ImCheck Awarded EUR 20.18 Million from the French Government Through the France 2030 Investment and Innovation Plan
• ImCheck Appoints Stephan Braun as Chief Medical Officer
• ImCheck to Present Promising ICT01 Data from the EVICTION Study at ASCO 2024
• ImCheck Therapeutics once again recognized for its potential to become an international leader in healthcare innovation
• ImCheck Presented Updated Positive Data from Phase I/IIa EVICTION-2 Trial of ICT01 in Combination with Low-dose IL-2 at SITC 2023
• ImCheck To Present EVICTION-2 Data on ICT01 Combination With Low Dose IL-2 In Patients with Advanced Solid Tumors at SITC Annual Meeting
• ImCheck to Present New Positive Data on ICT01 Monotherapy in Hematological Cancers at ESMO 2023
• View more press releases Close

Social media about ImCheck Therapeutics

• ImCheck Therapeutics on Wikipedia, Google News & Yahoo Finance
• ImCheck Therapeutics on LinkedIn, X (Twitter) & YouTube